Phase I Study Supports Therapeutic Potential of Polatuzumab Vedotin in non-Hodgkin Lymphoma. PSMA ADC Produces Clinically Relevant Declines in PSA and CTC Counts. Enhancing ADCs to Target Diseased Cells and Deliver Payloads. Seattle Genetics and Bristol-Myers Squibb Evaluate New Combination of Brentuximab Vedotin and Nivolumab. and Bristol-Myers Squibb Company have entered into a clinical trial collaboration to evaluate the investigational c.

How to Work with Adimab. Adimab Announces New Bispecific Antibody Collaboration with Sanofi. Adimab Announces Expansion of its Collaboration with GSK for the Discovery of Bispecific Antibodies.

A catch-all for information on Boston Area startups cribbed from various sources. These are included both as a nod to the information source provider and an FYI. Monday, October 20, 2008. In-Q-Tel Signs On To Back T2 Biosystems.

Crocker Ventures owns a minority equity position in these companies, which are run by independent management teams. Crocker Ventures owns a majority equity position in these companies and provides a significant operational contribution.

Cells, tissues, organs, organisms and ecologic niches are systems of components whose interactions have been defined and refined by evolution. The turn of the 21st century has been marked by a resurgence of interest in achieving a systems-level understanding of biology.

Merrimack Provides Business Update and Reports 2017 Financial Results. Strengthened the randomized Phase 2 SHERLOC study evaluating MM-121 in non-small cell lung cancer by expanding enrollment from 80 to 100 patients - - Dosed the first patient in randomized Phase 2 SHERBOC study evaluating MM-121 in metastatic breast cancer - - Announced the formation of a new.